浏览全部资源
扫码关注微信
- Journal Information
- Archive
- Submission
- For Reviewers
- Statement and Policies
Clinical observation of bevacizumab versus anlotinib respectively combined with chemotherapy drug in the treatment of EGFR-TKI acquired resistant advanced lung adenocarcinoma
- ZHONGGUO YAOFANG Vol. 34, Issue 20, Pages: 2525-2529(2023)
- 作者机构：
1.成都市第三人民医院肿瘤科，成都 610404
2.四川省妇幼保健院/四川省妇女儿童医院/成都医学院附属妇女儿童医院临床药学科，成都 610031
3.成都市第三人民医院心血管内科，成都 610404
- 作者简介：
- 基金信息：
DOI：10.6039/j.issn.1001-0408.2023.20.14
CLC： R979.1Published：30 October 2023，
Received：05 March 2023，
Revised：21 September 2023，
扫 描 看 全 文
齐彦宇,熊婷婷,张军等.贝伐珠单抗与安罗替尼分别联合化疗药用于EGFR-TKI获得性耐药晚期肺腺癌的临床观察 Δ[J].中国药房,2023,34(20):2525-2529.
QI Yanyu,XIONG Tingting,ZHANG Jun,et al.Clinical observation of bevacizumab versus anlotinib respectively combined with chemotherapy drug in the treatment of EGFR-TKI acquired resistant advanced lung adenocarcinoma[J].ZHONGGUO YAOFANG,2023,34(20):2525-2529.
齐彦宇,熊婷婷,张军等.贝伐珠单抗与安罗替尼分别联合化疗药用于EGFR-TKI获得性耐药晚期肺腺癌的临床观察 Δ[J].中国药房,2023,34(20):2525-2529. DOI： 10.6039/j.issn.1001-0408.2023.20.14.
QI Yanyu,XIONG Tingting,ZHANG Jun,et al.Clinical observation of bevacizumab versus anlotinib respectively combined with chemotherapy drug in the treatment of EGFR-TKI acquired resistant advanced lung adenocarcinoma[J].ZHONGGUO YAOFANG,2023,34(20):2525-2529. DOI： 10.6039/j.issn.1001-0408.2023.20.14.
摘要
目的
2
比较贝伐珠单抗与安罗替尼分别联合化疗药用于表皮生长因子受体-酪氨酸激酶抑制剂（EGFR-TKI）获得性耐药晚期肺腺癌的近期疗效和安全性。
方法
2
回顾性分析2019年6月－2021年10月成都市第三人民医院治疗的84例EGFR-TKI获得性耐药晚期肺腺癌患者资料，按用药的不同分为化疗组（32例）、安罗替尼联合化疗组（24例）和贝伐珠单抗联合化疗组（28例）。化疗组患者给予注射用培美曲塞二钠+卡铂注射液，并对症治疗不良反应；安罗替尼联合化疗组患者在化疗组用药的基础上，于化疗第1天口服盐酸安罗替尼胶囊10 mg，每日1次，连续用药14 d，停药7 d；贝伐珠单抗联合化疗组患者在化疗组用药的基础上，于化疗前1 d给予贝伐珠单抗注射液15 mg/kg，静脉滴注。3组患者均以每3周为1个周期，共治疗4个周期。比较3组患者的总有效率（ORR）、疾病控制率（DCR）、中位无进展生存期（mPFS），治疗前后血清中肿瘤标志物水平变化，并记录不良反应发生情况及随访1年的生存率。
结果
2
治疗4个周期后，两个联合化疗组患者的ORR、DCR均显著高于化疗组，mPFS均显著长于化疗组，且安罗替尼联合化疗组患者的DCR显著高于贝伐珠单抗联合化疗组（
P
＜0.05）。治疗4个周期后，3组患者血清中肿瘤标志物水平均显著低于同组治疗前，且两个联合化疗组均显著低于化疗组（
P
＜0.05）。3组患者恶心呕吐、骨髓抑制等不良反应发生率及1年生存率比较，差异均无统计学意义（
P
＞0.05）。
结论
2
贝伐珠单抗与安罗替尼分别联合化疗药用于EGFR-TKI获得性耐药晚期肺腺癌的疗效和安全性均较好。
Abstract
OBJECTIVE
2
To compare the short-term therapeutic effect and safety of bevacizumab versus anlotinib respectively combined with chemotherapy drug in the treatment of epidermal growth factor receptor tyrosine kinase inhibitors （EGFR-TKI） acquired resistant advanced lung adenocarcinoma.
METHODS
2
The information of 84 patients with EGFR-TKI acquired resistant advanced lung adenocarcinoma in the Third People’s Hospital of Chengdu was analyzed retrospectively during Jun. 2019-Oct. 2021. The patients were divided into chemotherapy group （32 cases）， anlotinib combined chemotherapy group （24 cases） and bevacizumab combined chemotherapy group （28 cases）. Patients in the chemotherapy group were given Pemetrexed disodium for injection and Carboplatin injection， and symptomatic treatment was given for adverse reactions. On the first day of chemotherapy， patients in the anlotinib combined chemotherapy group received Anlotinib hydrochloride capsules 10 mg orally， once a day， for 14 consecutive days and 7 days of discontinuation， based on the treatment of the chemotherapy group. Patients in the bevacizumab combined chemotherapy group were given Bevacizumab injection of 15 mg/kg intravenously 1 day before chemotherapy， based on the treatment of the chemotherapy group. Three groups of patients were treated for a total of four cycles， with one cycle every three weeks. The overall response rate （ORR）， disease control rate （DCR）， median progression-free survival （mPFS）， and the changes of serum tumor markers were compared among three groups before and after treatment； meanwhile， the occurrence of adverse drug reactions was recorded， and the 1-year survival rate was followed up.
RESULTS
2
After 4 treatment cycles， ORR and DCR of bevacizumab combined chemotherapy group and anlotinib combined chemotherapy group were higher than chemotherapy group （
P
＜0.05）； mPFS of the two groups were significantly longer than chemotherapy group， and DCR of anlotinib combined chemotherapy group was significantly higher than bevacizumab combined chemotherapy group （
P
＜0.05）. After 4 treatment cycles， the serum levels of tumor markers in three groups were significantly lower than before treatment， and both combined chemotherapy groups were significantly lower than chemotherapy group （
P
＜0.05）. There was no statistically significant difference in the incidence of adverse reactions such as nausea， vomiting， bone marrow suppression， and 1-year survival rate among the three groups of patients （
P
＞0.05）.
CONCLUSIONS
2
Bevacizumab and anlotinib combined with chemotherapy drug are effective and safe in the treatment of advanced lung adenocarcinoma with acquired EGFR-TKI resistance.
关键词
贝伐珠单抗安罗替尼表皮生长因子受体-酪氨酸激酶抑制剂肺腺癌
Keywords
anlotinibepidermal growth factor receptor-tyrosine kinase inhibitorslung adenocarcinoma
references
QIU H B，CAO S M，XU R H. Cancer incidence，morta-lity，and burden in China：a time-trend analysis and comparison with the United States and United Kingdom based on the global epidemiological data released in 2020[J]. Cancer Commun（Lond），2021，41（10）：1037-1048.
邹小农，贾漫漫，王鑫，等. 《2020全球癌症报告》要点解读[J]. 中国胸心血管外科临床杂志，2021，28（1）：11-18.
ZOU X N，JIA M M，WANG X，et al. Interpretation of the World Cancer Report 2020[J]. Chin J Clin Thorac Cardiovasc Surg，2021，28（1）：11-18.
吴海波，张小静，张银，等. IMRT联合同期TP方案治疗不可手术Ⅲ期非小细胞肺癌[J]. 西部医学，2020，32（9）：1342-1345，1349.
WU H B，ZHANG X J，ZHANG Y，et al. Efficacy of IMRT intensity-modulated radiotherapy combined with concurrent TP regimen in the treatment of inoperable stage Ⅲ non-small cell lung cancer[J]. Med J West China，2020，32（9）：1342-1345，1349.
HE J Y，HUANG Z R，HAN L Z，et al. Mechanisms and management of 3rd-generation EGFR-TKI resistance in advanced non-small cell lung cancer：review[J]. Int J Oncol，2021，59（5）：90.
POGODA L，ZIYLAN F，SMEEING D P J，et al. Bevacizumab as treatment option for recurrent respiratory papillomatosis：a systematic review[J]. Eur Arch Otorhinolaryngol，2022，279（9）：4229-4240.
DOHLMAN T H，MCSOLEY M，AMPARO F，et al. Bevacizumab in high-risk corneal transplantation：a pilot multicenter prospective randomized control trial[J]. Ophthalmology，2022，129（8）：865-879.
LIN B Y，SONG X M，YANG D W，et al. Anlotinib inhi-bits angiogenesis via suppressing the activation of VEGFR2，PDGFRβ and FGFR1[J]. Gene，2018，654：77-86.
韩宝惠，李凯，周彩存，等. 晚期非小细胞肺癌抗血管生成药物治疗中国专家共识（2019版）[J].中国肺癌杂志，2019，22（7）：401-412.
HAN B H，LI K，ZHOU C C，et al. Chinese expert consensus on antiangiogenic drugs for advanced non-small cell lung cancer：2019 edition[J]. Chin J Lung Cancer，2019，22（7）：401-412.
IANNESSI A，BEAUMONT H，LIU Y，et al. RECIST 1.1 and lesion selection：how to deal with ambiguity at baseline?[J]. Insights Imaging，2021，12（1）：36.
刘磊，索婷婷，张彦收，等. 病人在化疗后主观性不良事件评价中的作用[J]. 安徽医药，2020，24（6）：1268-1272，1277.
LIU L，SUO T T，ZHANG Y S，et al. Study on the role of patients in subjective adverse events assessment after chemotherapy[J]. Anhui Med Pharm J，2020，24（6）：1268-1272，1277.
ROSELL R，CARDONA A F，ARRIETA O，et al. Coregulation of pathways in lung cancer patients with EGFR mutation：therapeutic opportunities[J]. Br J Cancer，2021，125（12）：1602-1611.
KASHIMA Y，SHIBAHARA D，SUZUKI A，et al. Single-cell analyses reveal diverse mechanisms of resistance to EGFR tyrosine kinase inhibitors in lung cancer[J]. Cancer Res，2021，81（18）：4835-4848.
OHMORI T，YAMAOKA T，ANDO K，et al. Molecular and clinical features of EGFR-TKI-associated lung injury[J]. Int J Mol Sci，2021，22（2）：792.
KARAMI M，ERIKSEN E，OUWENEEL D M，et al. Long-term 5-year outcome of the randomized IMPRESS in severe shock trial：percutaneous mechanical circulatory support vs. intra-aortic balloon pump in cardiogenic shock after acute myocardial infarction[J]. Eur Heart J Acute Cardiovasc Care，2021，10（9）：1009-1015.
FURUKAWA K，NAGANO T，TACHIHARA M，et al. Interaction between immunotherapy and antiangiogenic therapy for cancer[J]. Molecules，2020，25（17）：3900.
AN D，BANERJEE S，LEE J M. Recent advancements of antiangiogenic combination therapies in ovarian cancer[J]. Cancer Treat Rev，2021，98：102224.
FERRARA R，IMBIMBO M，MALOUF R，et al. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer[J]. Cochrane Database Syst Rev，2021，4（4）：CD013257.
LU J，ZHANG W，YU K K，et al. Screening anlotinib responders via blood-based proteomics in non-small cell lung cancer[J]. FASEB J，2022，36（8）：e22465.
GARCIA J，HURWITZ H I，SANDLER A B，et al. Bevacizumab（Avastin®）in cancer treatment：a review of 15 years of clinical experience and future outlook[J]. Cancer Treat Rev，2020，86：102017.
杨雳，何杰，任召强，等. 安罗替尼治疗晚期非小细胞肺癌效果和安全性的Meta分析[J]. 中国医药，2020，15（4）：545-549.
YANG L，HE J，REN Z Q，et al. Efficacy and safety of anlotinib in treatment of advanced non-small cell lung cancer：a meta analysis[J]. China Med，2020，15（4）：545-549.
SHEN J，HUANG J，HUANG Y，et al. Anlotinib suppresses lung adenocarcinoma growth via inhibiting FASN-mediated lipid metabolism[J]. Ann Transl Med，2022，10（24）：1337.
HONG C，WEI J P，ZHOU T，et al. FGFR2-ERC1：a subtype of FGFR2 oncogenic fusion variant in lung adenocarcinoma and the response to anlotinib[J]. Onco Targets Ther，2022，15：651-657.
RICCARDI C，NAPOLITANO E，PLATELLA C，et al. Anti-VEGF DNA-based aptamers in cancer therapeutics and diagnostics[J]. Med Res Rev，2021，41（1）：464-506.
YANG Y L，CAO Y H. The impact of VEGF on cancer metastasis and systemic disease[J]. Semin Cancer Biol，2022，86（pt 3）：251-261.
ZSIROS E，LYNAM S，ATTWOOD K M，et al. Efficacy and safety of pembrolizumab in combination with bevacizumab and oral metronomic cyclophosphamide in the treatment of recurrent ovarian cancer：a phase 2 nonrandomized clinical trial[J]. JAMA Oncol，2021，7（1）：78-85.
SHI J H，CHENG Y，WANG Q M，et al. Anlotinib as third- or further-line therapy for short-term relapsed small-cell lung cancer：subgroup analysis of a randomized phase 2 study（ALTER1202）[J]. Front Med，2022，16（5）：766-772.
0
Views
6
下载量
0
CSCD
- L-PDFDownload
- WORDDownload
- Meta-XMLDownload
- BibTeXDownload
- EndnoteDownload
- RefMan Download
- NoteExpressDownload
- NoteFirstDownload
Publicity Resources
Related Articles
Related Author
Related Institution
- Address：8/F,129 Daping Main Street,Yuzhong District,Chongqing 400042,P.R.China
- Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号
公网安备50010302001817 - It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
- Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.